Ataluren
Becker Muscular Dystrophy
PTC TherapeuticsSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Becker Muscular Dystrophy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(-)-Epicatechin Craig McDonald, MD | Phase 2 | BB |
Tadalafil Cedars-Sinai Medical Center | Phase 4 | BB |
CARVEDILOL Catholic University, Italy | Phase 4 | BB |
Lisinopril Cooperative International Neuromuscular Research Group | Phase 2/3 | B |
RAMIPRIL Catholic University, Italy | Phase 4 | B |
View all 19 →
Same molecule, other indications
Ataluren is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →